share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Prasad Raju

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities

CRISPR Therapeutics | 4：持股變動聲明
SEC announcement ·  03/18 17:46
Moomoo AI 已提取核心訊息
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG (CRSP), completed a sale of 3,524 shares of common stock on March 15, 2024. The transaction was executed at a price of $72.69 per share, resulting in a total market value of $256,159.56. This sale followed an acquisition of 10,000 shares on March 14, 2024, through the exercise of derivative securities. After these transactions, Prasad's direct holdings in the company amount to 6,476 shares of common stock.
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG (CRSP), completed a sale of 3,524 shares of common stock on March 15, 2024. The transaction was executed at a price of $72.69 per share, resulting in a total market value of $256,159.56. This sale followed an acquisition of 10,000 shares on March 14, 2024, through the exercise of derivative securities. After these transactions, Prasad's direct holdings in the company amount to 6,476 shares of common stock.
CRISPR Therapeutics AG（CRSP）首席財務官拉朱·普拉薩德於2024年3月15日完成了3524股普通股的出售。該交易以每股72.69美元的價格執行，總市值爲256,159.56美元。此次出售是在2024年3月14日通過行使衍生證券收購了1萬股股票之後進行的。在這些交易之後，普拉薩德在公司的直接持有量爲6,476股普通股。
CRISPR Therapeutics AG（CRSP）首席財務官拉朱·普拉薩德於2024年3月15日完成了3524股普通股的出售。該交易以每股72.69美元的價格執行，總市值爲256,159.56美元。此次出售是在2024年3月14日通過行使衍生證券收購了1萬股股票之後進行的。在這些交易之後，普拉薩德在公司的直接持有量爲6,476股普通股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息